Connect Biopharma Holdings Limited (CNTB) Institutional Ownership & 13F Filings (Q2 2026)

CNTB ranks #20100 out of 37505 tracked stocks by institutional interest — a comparatively under-the-radar name outside the most closely tracked half.

1 institutions disclose a position in CNTB, but none treat it as a major bet — even Quadrature Capital Ltd, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

CNTB reported a net loss of $69.0M over the trailing twelve months.

• Not yet profitable — net loss of $69.0M over the trailing twelve months
• Revenue grew 50.3% year over year
• Net income declined year over year, from -$45.0M to -$69.0M
• Operating cash flow was negative, using $51.2M in cash
• Current ratio of 3.74x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.34x equity — within a conventional range